Hendry W G, Silke B, Taylor S H
Eur J Clin Pharmacol. 1981;19(5):323-7. doi: 10.1007/BF00544581.
The haemodynamic effects of intravenous metoprolol, over the dose-range 2.5--20 mg, were studied in 12 patients with coronary heart disease. The pharmacodynamic activity of the drug was confirmed by the suppression of exercise systolic pressure and tachycardia. There were statistically significant dose-response reductions in systolic and diastolic pressures, heart rate and cardiac output together with a dose-related increase in pulmonary wedge pressure. In patients with coronary heart disease intravenous metoprolol should probably not exceed the doses used in this study and should be administered with caution in patients with impairment of pumping function.
在12例冠心病患者中研究了静脉注射美托洛尔(剂量范围为2.5 - 20毫克)的血流动力学效应。运动时收缩压和心动过速受到抑制,证实了该药的药效学活性。收缩压、舒张压、心率和心输出量有统计学显著意义的剂量反应性降低,同时肺楔压有剂量相关性升高。对于冠心病患者,静脉注射美托洛尔可能不应超过本研究中使用的剂量,对于泵功能受损的患者应谨慎给药。